The EGFR-Tyrosine Kinase Inhibitors (EGFR-TKIs) and Immune Checkpoint Inhibitors (ICIs) for Non-Small Cell Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 109
Special Issue Editors
Interests: malignant pleural mesothelioma; lung cancer; molecular pathology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related death worldwide. Substantial molecular heterogeneity at diagnosis further complicates treatment choices and efficacy. However, recent advancements in molecular characterization, mainly for adenocarcinoma histotype, in addition to a better understanding of the immune context of the tumor, are dramatically changing the course of NSCLC patients. At the same time, emerging data on the efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and of immune checkpoint inhibitors (ICIs) for NSCLC showcase the need for comprehensive molecular profiling, including of EGFR mutation and PD-L1 status, to tailor treatment strategies. Research into the effectiveness of target and immune-based therapies is extending from local advanced to early-stage NSCLC, delivering positive outcomes and increasingly expanding the role of surgery in stages otherwise traditionally excluded.
Consequently, this growing knowledge highlights the pressing need for enhanced testing procedures, across early diagnosis to advanced disease, ensuring the best treatment option for each patient in the context of precision medicine. In addition, molecular investigations of lung cancer are warranted to uncover and face resistance mechanisms to therapy and identify new predictive biomarkers.
This Special Issue, involving experts in the field, welcomes original articles, case reports, reviews and metanalyses on current insights and upcoming advances in target therapy and immunotherapy, with particular attention to new developments in biomolecular testing and the role of surgery in NSCLC.
We look forward to receiving your contributions.
Dr. Greta Alì
Dr. Maria Giovanna Mastromarino
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-small cell lung cancer
- target therapy
- EGFR-tyrosine kinase inhibitors
- immunotherapy
- immune checkpoint inhibitors
- molecular analysis
- surgery
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
